• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Increased Number of Prostate Cancer Patients Selecting High Dose-Rate Interstitial Brachytherapy during the COVID-19 Pandemic
Since the beginning of the outbreak of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19) in December 2019 in Wuhan, China [1], the virus rapidly spread around the globe. The virus hardly hit not only European countries, but also the United States, Brazil, and India. Subsequently, the World Health Organization has declared the COVID-19 outbreak a global pandemic on March 12th 2020 and many large cities around the world experienced lock-down. Several organizations or radiotherapy societies published guidelines or suggested solutions for cancer patient ’s management under the global COVID-19 pandemic [2–10].
Source: Radiotherapy and Oncology - November 20, 2020 Category: Radiology Authors: Naoya Murakami, Satoshi Nakamura, Tairo Kashihara, Koji Inaba, Tomoya Kaneda, Kana Takahashi, Kae Okuma, Hiroshi Igaki, Jun Itami Tags: Letter to the Editor Source Type: research

Human, Nonhuman Primate, and Bat Cells Are Broadly Susceptible to Tibrovirus Particle Cell Entry
Discussion Tibroviruses are highly undercharacterized rhabdoviruses with unknown pathogenic potential. All isolated tibroviruses (BAV, BHV, CPV, SWBV, and TIBV) have only been found in biting midge vectors or in various, apparently healthy non-human mammals (Cybinski et al., 1980; Standfast et al., 1984; Cybinski and Gard, 1986; Gibbs et al., 1989). The discovery of BASV, EKV-1, and EKV-2 genomes in human sera (Grard et al., 2012; Stremlau et al., 2015) suggests that at least some tibroviruses could infect humans. Because BASV was discovered in the serum of a severely ill individual, tibroviruses should be considered pote...
Source: Frontiers in Microbiology - April 25, 2019 Category: Microbiology Source Type: research